The failure early this month of Ribozyme Pharmaceuticals Inc.'s Angiozyme in a Phase II trial as a monotherapy against Stage IV metastatic breast cancer was enough to feed another round in the sporadic, ongoing debate over angiogenesis inhibitors. (BioWorld Financial Watch)

Erectile dysfunction (ED) used to be called impotence, until doctors decided on what the Merck Manual of Diagnosis and Therapy refers to as a "less pejorative" and more specific phrase. (BioWorld Financial Watch)

Talk about “validation.” The buzzword often used in discussing deals fits perfectly Genta Inc.’s potential $480 million agreement with Aventis SA to develop the former’s drug Genasense (G3139), the first antisense oncology compound - already in multiple Phase III trials - to target the Bcl-2 protein and boost the effectiveness of chemotherapy. (BioWorld Today)

As if implications of the Enron Corp. situation hadn't already messed things up enough for biotechnology (and just about every other sector that uses balance sheets and ledgers), another spawn of the scandal has reared its head for industry leaders to fear and loathe. (BioWorld Financial Watch)